Researchers at Voronoi Bio Inc. and Voronoi Inc. have disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, rheumatoid arthritis, myocardial infarction, Alzheimer's disease, asthma and type 1 diabetes, among others.
Quest Diagnostics Inc. evidently found what it was looking for, as it agreed to acquire Haystack Oncology Inc. in an all-cash deal valued at up to $450 million with $300 million at closing and $150 million contingent on meeting specific milestones. Haystack focuses on minimal residual disease (MRD) testing, which can detect residual or recurring cancer in its early stages and help guide therapy decisions using blood samples rather than biopsied tissue. The companies expect the transaction to close before the end of June.
Astrazeneca has described spirocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified macrocyclic compounds acting as GTPase KRAS (G12C) mutant inhibitors reported to be useful for the treatment of cancer.
CD73 is known to induce immune evasion in solid tumors by release of immune-suppressive adenosine in the tumor microenvironment. Researchers from Cidara Therapeutics Inc. have presented preclinical data on the CD73 inhibitor drug FC-conjugate CBO-212 for the potential treatment of solid tumors.
Medshine Discovery Inc. has divulged nuclear receptor ROR-γ (RORC) agonists or RORC inverse agonists reported to be useful for the treatment of cancer.
